Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$59.95 USD

59.95
4,196,031

+1.47 (2.51%)

Updated Nov 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Moderna Collaborates With Catalent for Coronavirus Vaccine

by Zacks Equity Research

Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.

Ritujay Ghosh headshot

3 Stocks to Buy as Companies Speed Up Vaccine Production

by Ritujay Ghosh

Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.

Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Catalent (CTLT) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 2.04% and 10.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PCRX or CTLT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PCRX vs. CTLT: Which Stock Is the Better Value Option?

Catalent (CTLT) Reports Next Week: What to Expect

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Matches Q2 Earnings Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 0.00% and 3.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Reports Next Week: What You Should Expect

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 8.33% and 4.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

CTLT or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

Lannett (LCI) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Catalent (CTLT) Upgraded to Buy: Here's Why

by Zacks Equity Research

Catalent (CTLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Catalent (CTLT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 9.38% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Catalent (CTLT) Q4 Earnings Expected to Decline

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock?

by Zacks Equity Research

Medtronic (MDT) is encouraged by robust and consistent constant currency growth in the RTG business over the last few quarters.

Medtronic (MDT) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Medtronic's (MDT) successful execution of growth policies should aid earnings results in the fiscal first quarter.

Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.

Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CTLT vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

CTLT vs. ZTS: Which Stock Is the Better Value Option?

Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).